NanOlogy, a Fort Worth-based clinical-stage oncology company, has appointed John M. Goldberg, MD, as fractional chief medical officer to advance the development of its Large Surface Area Microparticle (LSAM) drug portfolio.
The portfolio includes NanOlogy’s development program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brain cancer with limited treatment options.
Goldberg is a graduate of the University of Massachusetts Chan Medical School and is board-certified in pediatric hematology/oncology, with more than 20 years of experience in all phases of drug development, from early research through late-phase clinical trials, NanOlogy said.
His most recent roles as CMO have included positions at Rafael Holding, a healthcare investment, family office, and biotechnology company, and at Oncorus, a biopharmaceutical company developing an intratumorally delivered viral immunotherapy for cancer.
Earlier in his career, Goldberg served as senior medical director at H3 Biomedicine Inc. (a research subsidiary of Eisai) and as medical director at Agenus. He was also a part-time lecturer at Harvard Medical School and an associate professor at the University of Miami Miller School of Medicine, NanOlogy said.
“As we progress our DIPG program toward initiating a clinical trial in late 2026 and advance our clinical-stage investigational drugs into late-phase clinical trials, John will play a critical role in our development strategy and execution,” NanOlogy CEO David Arthur said in a statement. “John’s broad expertise across both drug development and business strategy will strengthen our ability to rapidly advance these programs.”
Arthur is fresh on the scene himself at NanOlogy. He took up his post in December as the company moved toward later-stage development and commercialization. Founder H. Paul Dorman remains chairman of the company.
Seeking ‘the best clinical pathway’
Goldberg said he is impressed by NanOlogy’s progress and believes his experience, “including development of intratumoral therapies, positions me well to contribute to NanOlogy’s future success.”
“My initial priorities are to advance the DIPG program and select the best clinical pathway for our adult solid tumor investigational drugs,” Goldberg added. “I’m looking forward to our progress and the benefit it may hold for cancer patients.”
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
-
The MotiliCap capsule system offers a non-invasive, high-tech way to assess how the gastrointestinal tract is functioning — giving clinicians advanced insights into digestive health and movement.
-
Led by a James Beard Award–winning chef, the 20-course experience will unfold inside a 9,500-square-foot warehouse, with projection-mapped dining rooms and just 26 seats per seating. It’s all part of what the founders call a love letter to Dallas.
-
The city council approved Tap Telehealth from Dallas-based MD Health Pathways. With that vote, Garland became the largest city so far to adopt the on-demand healthcare program, which will be offered as an opt-out service on residents’ utility bills.
-
A team of UT Dallas computer scientists has partnered with Plano-based CorroHealth to introduce "reasoning" to the company's LLM- and NLP-based coding automation technology. "The goal is to extract knowledge like a human would do it," said UTD's Dr. Gopal Gupta.
